about sade group

Established in 2015, and founded by a team of highly experienced life science executives, agri-tech experts and serial entrepreneurs, Sade is focused on realizing the promise of medical cannabis through key activities that include Sade Biotech, Medical420 & Cannabivar

sade biotech

initially established to research, manage and develop science-backed and evidence-based medicinal cannabis products, Sadé Biotech initiated several pre-clinical and clinical studies. These studies were seeking unique formulations and chemical compositions to treat specific medical symptoms. The result of three years of research was ASAYA™, a real-time digital healthcare platform built upon human and machine learning to power better care for patients.
Sade Biotech also developed and designed a smart, connected medical device –a unique mechanism that enables to administer a precise, consistent dose of medical cannabis oil along with improving its stability and quality. Using Bluetooth technology and interconnected to a smartphone, the device will help monitor treatment and provide precision on both chemovar as well as dosage.


Cultivating medical grade cannabis varieties, through advanced agriculture and breeding technologies, in its state of the art indoor hydroponic facility in North Macedonia.


Partnerships and investment in plant genetics mapping and analysis, and clinical research.

Group structure



plant genetics research






Pharma-Grade INDOOR Cultivation

our Journey

The company was founded as a leading scientific research company and initially worked in conjunction with the ARO, Israel’s governmental Agriculture Research Organization, but has since expanded its activities to include global and commercial cultivation, scientific research and the development of big data AI solutions.


Sade Ltd. is established and invested seed money in four Cannabis funded researches. All researches performed under Israel’s governmental institute of Agriculture Development: The ARO (Vulcani Center). Sade obtained its first Medical Cannabis permit to operate


Two of the funded researches matured to commercial companies:

  • Plantext: Developed unique formulations for the treatment of Crohn’s & Colitis
  • Cannabivar: Identifying key genes that are responsible for metabolic pathways creating key chemical compounds in the Cannabis trichome
  • Sade establishes MEDICAL420 in North Macedonia – and raises funding towards the planning and construction of a state-of-the-art indoor facility cultivating and processing Medical Cannabis.
  • Sade helps raise over $3.5M, mostly in Canada, to its daughter company, Plantext
  • MEDICAL420 receives its federal license to cultivate and sell Medical Cannabis in North Macedonia
  • In late 2018, the first successful crop of MEDICAL420 is being harvested
  • SADE closes a round of financing from Industry leaders, towards the development of SADE BIOTECH, its technology and science arm. Additional use of proceeds towards obtaining GACP certification in its North Macedonia facility
  • Sade launches the development of ASAYA – a big data software platform to help healthcare providers and patients transform Medical Cannabis care

Sade Biotech launches prototype of ASAYA big-data AI platform, including Healthcare Providers dashboard and Patients mobile app

medical 420


An indoor facility that opens the doors to the European market. Sadé’s Medical420 – North Macedonia facility, is 3,000 square meters in size and currently yields roughly 3,500 kg of highest-grade cannabis for pharmaceutical use each year. The facility is slated to undergo a massive expansion that will extend its working space by another 30,000 square meters, enabling its annual cannabis output to grow to 20,000 kg.



Please join our ever-growing group of early adaptors. If you are a medical cannabis patient, user, healthcare provider, researcher or fan – and have information to share with the world: please click below, fill in brief info and join our journey.